| Stereochemistry | RACEMIC |
| Molecular Formula | C15H16N2O2 |
| Molecular Weight | 256.2997 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C1=CC2=C(CC(CN3C=CN=C3)CC2)C=C1
InChI
InChIKey=VJJHOPPXRPHVCA-UHFFFAOYSA-N
InChI=1S/C15H16N2O2/c18-15(19)14-4-3-12-7-11(1-2-13(12)8-14)9-17-6-5-16-10-17/h3-6,8,10-11H,1-2,7,9H2,(H,18,19)
| Molecular Formula | C15H16N2O2 |
| Molecular Weight | 256.2997 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
Japanese normal male volunteers received repeated oral doses of 200 mg every 12 h for 4 doses, or 400 mg every 24 h for 2 doses, or 200 mg every 12 h for 14 doses.
Route of Administration:
Oral
|
|
ENANTIOMER -> RACEMATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 4 of 4 entries
